PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Children0 citationsOpen Access

Clinical Efficacy and Safety of Shenqu Xiaoshi Oral Liquid for Functional Constipation in Children: A Systematic Review and Meta-Analysis

View Full Paper
SLShen LiHXHui XuTGTian Geng

Key Points

  • This review aims to assess the efficacy and safety of Shenqu Xiaoshi Oral Liquid for treating functional constipation in children.
  • Comprehensive literature search conducted across multiple databases.
  • Quantitative analysis using mean difference for continuous outcomes and risk ratio for dichotomous outcomes.
  • Assessment of methodological quality using the Cochrane risk of bias tool.
  • Statistical analyses performed using RevMan 5.3 and Stata 13 software.
  • Shenqu Xiaoshi Oral Liquid showed superior clinical effectiveness compared to the control group (RR = 1.36).
  • Post-treatment defecation intervals were significantly shorter in the treatment group (WMD = -0.91).
  • Lower recurrence rate observed in the treatment group (RR = 0.49).
  • No significant differences in adverse reactions between the two groups.
  • Higher serum levels of motilin and gastrin were noted in the treatment group.

Abstract

Aim: We aimed to evaluate the clinical efficacy and safety of Shenqu Xiaoshi Oral Liquid in the treatment of functional constipation in children. Methods: A comprehensive literature search was conducted from inception to 20 October 2025, across PubMed, Embase, Scopus, Web of Science, the Cochrane Library, Chinese VIP Information Database, China National Knowledge Infrastructure (CNKI), and Wan Fang Med Database. For quantitative analysis, the mean difference (MD) was used for continuous outcomes and the risk ratio (RR) for dichotomous outcomes. The methodological quality of the included studies was assessed using the Cochrane risk of bias tool. Statistical analyses were performed using RevMan 5.3 and Stata 13 software. Results: Eight studies involving 692 pediatric patients were included (Shenqu Xiaoshi Oral Liquid group: 345; control group: 347). Compared to the control group, Shenqu Xiaoshi Oral Liquid demonstrated superior clinical effectiveness RR = 1.36, 95% CI: (1.25, 1.47); z = 7.11, p < 0.00001 and a lower recurrence rate RR = 0.49, 95% CI: (0.26, 0.93); z = 2.18, p = 0.03. Both the post-treatment WMD = −0.91, 95% CI: (−0.97, −0.86); z = 31.94, p < 0.00001 and post-recurrence WMD = −1.49, 95% CI: (−1.56, −1.41); z = 40.12, p < 0.00001 defecation intervals were shorter in the Shenqu Xiaoshi Oral Liquid group. No significant difference was observed in the incidence of adverse reactions between the two groups RR = 0.67, 95% CI: (0.35, 1.29); z = 1.20, p = 0.23. Furthermore, serum levels of motilin WMD = 41.66, 95% CI: (34.17, 49.16); z = 10.90, p < 0.00001 and gastrin WMD = 23.74, 95% CI: (7.30, 40.19); z = 2.83, p = 0.005 were significantly higher in the Shenqu Xiaoshi Oral Liquid group. Conclusions: Shenqu Xiaoshi Oral Liquid shows favorable clinical efficacy and an acceptable safety profile for treating functional constipation in children. However, these outcome measures are influenced by the limited sample size and potential heterogeneity of the included studies, warranting cautious interpretation of the results.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69c8c43ede0f0f753b39efb8https://doi.org/10.3390/children13040464
Ask AI
Helpful
Bookmark
Share
View Full Paper